AbbVie Profit Margin 2010-2023 | ABBV

Current and historical gross margin, operating margin and net profit margin for AbbVie (ABBV) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. AbbVie net profit margin as of December 31, 2023 is 8.95%.
AbbVie Annual Profit Margins
AbbVie Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $316.181B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $726.876B 121.04
Novo Nordisk (NVO) Denmark $548.511B 45.19
Johnson & Johnson (JNJ) United States $387.763B 15.43
Merck (MRK) United States $326.787B 86.02
Novartis AG (NVS) Switzerland $218.637B 15.15
AstraZeneca (AZN) United Kingdom $205.648B 18.22
Pfizer (PFE) United States $151.842B 14.69
Sanofi (SNY) $121.951B 10.98
Innoviva (INVA) United States $0.985B 8.88